p53-based anti-cancer therapies: An empty promise?

Current Issues in Molecular Biology

Volumn 12, Issue 3, 2010, Pages 143-146

  Desilet, Nikolas ^a   Campbell, Tessa N ^b   Choy, Francis Y M ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; MI 63; MICRORNA; NUTLIN 3; NUTLIN DERIVATIVE; ONCOLYTIC ADENOVIRUS; PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; QUINOLINOL DERIVATIVE; RETROVIRUS VECTOR; SPIROOXINDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL DIFFERENTIATION; CELLULAR STRESS RESPONSE; COLON CARCINOMA; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; GENE MUTATION; GENOTOXICITY; HUMAN; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SENESCENCE; VIRAL GENE THERAPY;

ANIMALS; HUMANS; MICE; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950540620     PISSN: 14673037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alsafadi, S., Tourpin, S., Andre, F., Vassal, G., and Ahomadegbe, J.C. (2009). p53 family: at the crossroads in cancer therapy. Curr. Med. Chem. [epub ahead of print].
2. Aparicio, S. and Eaves, C.J. (2009). p53: a new kingpin in the stem cell arena. Cell 138, 1060-1062.
3. Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., vanTuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., White, R., and Vogelstein, B. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-221.
4. Bommer, G.T., Gerin, I., Feng, Y., Kaczorowski, A.J., Kuick, R., Love, R.E., Zhai, Y., Giordano, T.J., Qin, Z.S., Moore, B.B., MacDougald, O.A., Cho, K.R., and Fearon, E.R. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17, 1298-1307.
5. Bouchet, B.P., de Fromentel, C.C., Puisieux, A., and Galmarini, C.M. (2006). p53 as a target for anti-cancer drug development. Crit. Rev. Oncol. Hematol. 58, 190-207.
6. Burdelya, L.G., Komarova, E.A., Hill, J.E., Browder, T., Tararova, N.D., Mavrakis, L., Dicorleto, P.E., Folkman, J., and Gudkov, A.V. (2006). Inhibition of p53 response in tumour stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res. 66, 9356-9361.
7. Campbell, T.N. and Choy, F.Y.M. (2005). RNA interference: past, present and future. Curr. Issues Mol. Biol. 7, 1-6.
8. Canner, J.A., Sobo, M., Ball, S., Hutzen, B., de Angelis, S., Willis, W., Studebaker, A.W., Ding, K., Wang, S., Yang, D., and Lin, J. (2009). MI-63: a novel small molecular inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Brit. J. Cancer 101, 774-781.
9. Chang, C., Simmons, D.T., Martin, M.A., and Mora, P.T. (1979). Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J. Virol. 31, 463-471.
10. Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C.J., Arking, D.E., Beer, M.A., Maitra, A., and Mendell, J.T. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745-752.
11. Chari, N.S., Pinaire, N.L., Thorpe, L., Medeiros, L.J., Routbort, M.J., and McDonnell, T.J. (2009). The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 14, 336-347.
12. Cheok, C.F., Dey, A., and Lane, D.P. (2007). Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol. Cancer Res. 5, 1133-1145.
13. Corney, D.C., Flesken-Nikitin, A., Godwin, A.K., Wang, W., and Nikitin, A.Y. (2007). MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67, 8433-8438.
14. Eliyahu, D., Raz, A., Gruss, P., Givol, D., and Oren, M. (1984). Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312, 646-649.
15. Finlay, C.A., Hinds, P.W., and Levine, A.J. (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093.
16. Fuster, J.J., Sanz-Gonzalez, S.M., Moll, U.M., and Andres, V. (2007). Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 13, 192-199.
17. Graat, H.C.A., Carette, J.E., Schagen, F.H.E., Vassilev, L.T., Gerritsen, W.R., Kaspers, G.J.L., Wuisman, P.I.J.M., and van Beusechem, V.W. (2007). Enhanced tumor kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol. Cancer Ther. 6, 1552-1561.
18. Gudkov, A.V. and Komarova, E.A. (2007). Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum. Mol. Genet. 16, R67-R72.
19. Hainaut, P. and Wiman, K.G. (2009). 30 years and a long way into p53 research. Lancet Oncol. 10, 913-919.
20. He, I., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., Jackson, A.L., Linsley, P.S., Chen, C., Lowe, S.W., Cleary, M.A., and Hannon, G.J. (2007). A microRNA component of the p53 tumor suppressor network. Nature 447, 1130-1134.
21. Hinds, P., Finlay, C., and Levine, A.J. (1989). Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63, 739-746.
22. Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., and Yamanaka, S. (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135.
23. Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., Wahl, G.M., and Belmonte, J.C.I. (2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460, 1140-1144.
24. Kress, M., May, E., Cassingena, R., and May, P. (1979). Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J. Virol. 31, 472-483.
25. Krizhanovsky, V. and Lowe, S.W. (2009). The promises and perils of p53. Nature 460, 1085-1086.
26. Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16.
27. Lane, D.P. and Crawford, L.V. (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263.
28. Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M.A., and Serrano, M. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136-1139.
29. Lim, Y.P., Lim, T.T., Chan, Y.L., Song, A.C., Yeo, B.H., Vojtesek, B., Coomber, D., Rajagopal, G., and Lane, D. (2007). The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 26, 1517-1521.
30. Linzer, D.I. and Levine, A.J. (1979). Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52.
31. Marión, R.M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., and Blasco, M.A. (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149-1153.
32. Melero, J.A., Stitt, D.T., Mangel, W.F., and Carroll, R.B. (1979). Identification of new polypeptide species (48-55 K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology 93, 466-480.
33. Metias, S.M., Lianidou, E., and Yousef, G.M. (2009). MicroRNAs in clinical oncology: at the crossroads between promises and problems. J. Clin. Pathol. 62, 771-776.
34. Parada, L.F., Land, H., Weinberg, R.A., Wolf, D., and Rotter, V. (1984). Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312, 649-651.
35. Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., and Oren, M. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell. 26, 731-743.
36. Shangary, S. and Wang, S. (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Ann. Rev. Pharmacol. Toxicol. 49, 223-241.
37. Utikal, J., Polo, J.M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R.M., Khalil, A., Rheinwald, J.G., and Hochedlinger, K. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145-1148.
38. Vazquez, A., Bond, E.E., Levine, A.J., and Bond, G.L. (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Rev. Drug Discovery 7, 979-987.
39. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R., and Jacks, T. (2007). Restoration of p53 function leads to tumor regression in vivo. Nature 445, 661-665.
40. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
41. Yamakuchi, M., Ferlito, M., and Lowenstein, C.J. (2008). mir34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 105, 13421-13426.